title: Monocyte apoptosis in dialysis patients is Fas ligand-mediated.
abstract: BACKGROUND
  The mononuclear phagocyte system plays an important role in host defense. Since dialysis patients have been reported to show enhanced leukocytes apoptosis, we evaluated the mechanism of increased apoptosis of monocytes in dialysis patients.
  
  
  METHODS
  Apoptotic studies were carried out on monocytes isolated from dialysis patients as well as healthy subjects. The effect of dialysis sera and membranes was evaluated on monocyte apoptosis as well as monocyte expression of proapoptotic proteins such as Fas and FasL. To confirm the role of FasL, we evaluated the effect of activated secretory products on T cell apoptosis. In addition, we studied FasL content of dialysis sera and supernatants of activated monocytes.
  
  
  RESULTS
  Monocytes isolated from dialysis patients (MDP) showed a greater magnitude of apoptosis when compared to monocytes isolated from healthy subjects (MHS) (MHS, 3.6 +/- 1.1% vs. MDP, 24.3 +/-1.4%). Sera of hemodialysis patients (SHD) promoted (p < 0.001) apoptosis of MHS when compared to pooled control sera (HPS) (HPS, 0.8 +/- 0.5% vs. SHD, 11.5 +/- 0.5% apoptotic cells/field). Dialysis membranes, cellulose acetate membranes in particular, promoted monocyte apoptosis. Interestingly, anti-FasL antibodies partly inhibited dialysis sera-induced monocyte apoptosis. Dialysis membranes also modulated monocyte expression of both Fas and FasL. Secretory products of activated monocytes also promoted T cell apoptosis. Dialysis sera and activated monocyte secretory products showed increased FasL content.
  
  
  CONCLUSIONS
  These results suggest that dialysis patients have an increased rate of monocyte apoptosis, which is mediated through a uremic milieu (serum factors). One of these serum factors seems to be FasL. In addition, dialysis membranes seem to promote apoptosis independent of the uremic milieu. The present study provides a mechanistical insight into the enhanced apoptosis of monocytes in dialysis patients.
authors.affiliation: Department of Medicine, Long Island Jewish Medical Center, New Hyde Park, New York 11040, USA. singhal@lij.edu
authors.forename: R
authors.initials: R
authors.lastname: Ranjan
authors.forename: H
authors.initials: H
authors.lastname: Shah
authors.forename: J
authors.initials: J
authors.lastname: Siu
authors.forename: E
authors.initials: E
authors.lastname: Varghese
authors.forename: M
authors.initials: M
authors.lastname: Bhaskaran
authors.forename: K
authors.initials: K
authors.lastname: Reddy
authors.forename: A A
authors.initials: AA
authors.lastname: Kapasi
authors.forename: J D
authors.initials: JD
authors.lastname: Wagner
authors.forename: P C
authors.initials: PC
authors.lastname: Singhal
mesh_terms: D017209:Apoptosis; D015153:Blotting, Western; D004797:Enzyme-Linked Immunosorbent Assay; D053222:Fas Ligand Protein; D005260:Female; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000502:physiology*; D008567:Membranes, Artificial; D008875:Middle Aged; D009000:Monocytes; D006435:Renal Dialysis
chemical_list: C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D008567:Membranes, Artificial